October 23, 2025Open Access

Impact of the first nirsevimab immunization campaign on RSV-related emergency department visits and hospitalizations in Québec, Canada

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Evaluation shows nirsevimab reduces RSV-related hospitalizations and emergency department visits in infants, indicating effective intervention.

Hospitalizations decreased by 66% for RSV cases in infants, demonstrating significant prevention impact.
Emergency department visits for acute bronchiolitis dropped by 35%, highlighting the program's effectiveness.
Active surveillance data was used alongside administrative health data to measure RSV impacts during the 2024-2025 season.
Results point to a successful universal immunization campaign against RSV in Québec, warranting further research.

Bemmo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Evaluation shows nirsevimab reduces RSV-related hospitalizations and emergency department visits in infants, indicating effective intervention.